Sandoz exec to take up the reins at Stada Arz

2 February 2018

Peter Goldschmidt will join Stada Arzneimittel on September 1, 2018 and will succeed Claudio Albrecht as chief executive, making him the fifth CEO since 2016 of the German drugmaker, which was taken over last fall by Bain Capital and Cinven in a deal valuing the firm at 4.1 billion euros (~$5 billion at current exchange rates).

Mr Goldschmidt is joining the company from Novartis (NOVN: VX), where he has held various leadership positions in Europe, Asia and the USA over the past 28 years. He is currently president of Sandoz USA and head North America.

A resolution to that effect was passed at a meeting of the company's supervisory board yesterday. An experienced manager in the OTC and generic drug segment, Mr Goldschmidt will build on the successful course of renewal and growth at Stada which Claudio Albrecht will continue pursuing until the transition of the CEO role. As previously announced, Mr Albrecht will then move on to a non-executive position within the group of companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK